NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
(Total Views: 278)
Posted On: 08/17/2021 4:46:12 PM
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as well as ANPC’s commercialization efforts to drive adoption and growth of its Cancer Differentiation Analysis (“CDA”) technology. CDA is ANPC’s flagship product for cancer screening and early detection. Pandit has more than two decades of experience with leading precision medicine strategies, molecular and companion diagnostic approaches and technologies in the pharmaceutical and diagnostics industries. Pandit has served in positions of increasing responsibility at major diagnostics and pharmaceutical companies including Janssen Diagnostics, Siemens Healthcare Diagnostics, National Institutes of Health and GlaxoSmithKline; he also has seven granted patents and has received numerous awards and honors throughout his career. ANPC also noted that Pandit has successfully managed complex projects and boasts a strong track record in delivering in-vitro diagnostic (“IVD”) products to the marketplace. A licensed CLIA laboratory director, Pandit will continue to serve as AnPac Bio’s laboratory director for its CLIA-certified laboratory. “I warmly welcome Dr. Pandit to our management team,” said AnPac Bio chairman of the board Dr. Chris Yu in the press release. “His academic background, extensive life science work experience, including diagnostic product development, strong program management and commercialization experience at multiple global leading companies will greatly benefit AnPac Bio in our pursuit of U.S. growth and commercialization of CDA technology.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as well as ANPC’s commercialization efforts to drive adoption and growth of its Cancer Differentiation Analysis (“CDA”) technology. CDA is ANPC’s flagship product for cancer screening and early detection. Pandit has more than two decades of experience with leading precision medicine strategies, molecular and companion diagnostic approaches and technologies in the pharmaceutical and diagnostics industries. Pandit has served in positions of increasing responsibility at major diagnostics and pharmaceutical companies including Janssen Diagnostics, Siemens Healthcare Diagnostics, National Institutes of Health and GlaxoSmithKline; he also has seven granted patents and has received numerous awards and honors throughout his career. ANPC also noted that Pandit has successfully managed complex projects and boasts a strong track record in delivering in-vitro diagnostic (“IVD”) products to the marketplace. A licensed CLIA laboratory director, Pandit will continue to serve as AnPac Bio’s laboratory director for its CLIA-certified laboratory. “I warmly welcome Dr. Pandit to our management team,” said AnPac Bio chairman of the board Dr. Chris Yu in the press release. “His academic background, extensive life science work experience, including diagnostic product development, strong program management and commercialization experience at multiple global leading companies will greatly benefit AnPac Bio in our pursuit of U.S. growth and commercialization of CDA technology.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)